Literature DB >> 35624002

Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

Lizhi Pang1, Fatima Khan1, Amy B Heimberger1, Peiwen Chen2.   

Abstract

Glioblastoma (GBM) is the most aggressive and lethal form of brain tumor in human adults. Myeloid-lineage cells, including macrophages, microglia, myeloid-derived suppressor cells (MDSCs), and neutrophils, are the most frequent types of cell in the GBM tumor microenvironment (TME) that contribute to tumor progression. Emerging experimental evidence indicates that symbiotic interactions between cancer cells and myeloid cells are critical for tumor growth and immunotherapy resistance in GBM. In this review, we discuss the molecular mechanisms whereby cancer cells shape a myeloid cell-mediated immunosuppressive TME and, reciprocally, how such myeloid cells affect tumor progression and immunotherapy efficiency in GBM. Moreover, we highlight tumor-T cell symbiosis and summarize immunotherapeutic strategies intercepting this co-dependency in GBM.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MDSCs; glioblastoma; immunotherapy; macrophages; microglia; symbiosis

Mesh:

Year:  2022        PMID: 35624002      PMCID: PMC9492629          DOI: 10.1016/j.trecan.2022.04.010

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  133 in total

1.  Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.

Authors:  Baisakhi Raychaudhuri; Patricia Rayman; Pengjing Huang; Matthew Grabowski; Dolores Hambardzumyan; James H Finke; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2015-01-13       Impact factor: 4.130

2.  Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis.

Authors:  Maximilian O Schaettler; Megan M Richters; Malachi Griffith; Gavin P Dunn; Anthony Z Wang; Zachary L Skidmore; Bryan Fisk; Katherine E Miller; Tammi L Vickery; Albert H Kim; Michael R Chicoine; Joshua W Osbun; Eric C Leuthardt; Joshua L Dowling; Gregory J Zipfel; Ralph G Dacey; Hsiang-Chih Lu; Tanner M Johanns; Obi L Griffith; Elaine R Mardis
Journal:  Cancer Discov       Date:  2021-10-05       Impact factor: 38.272

3.  Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity.

Authors:  Reza Mirzaei; Susobhan Sarkar; Lauren Dzikowski; Khalil S Rawji; Lubaba Khan; Andreas Faissner; Pinaki Bose; V Wee Yong
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

4.  Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma.

Authors:  Dongrui Wang; Renate Starr; Wen-Chung Chang; Brenda Aguilar; Darya Alizadeh; Sarah L Wright; Xin Yang; Alfonso Brito; Aniee Sarkissian; Julie R Ostberg; Li Li; Yanhong Shi; Margarita Gutova; Karen Aboody; Behnam Badie; Stephen J Forman; Michael E Barish; Christine E Brown
Journal:  Sci Transl Med       Date:  2020-03-04       Impact factor: 17.956

5.  IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.

Authors:  Erik Ladomersky; Lijie Zhai; Alicia Lenzen; Kristen L Lauing; Jun Qian; Denise M Scholtens; Galina Gritsina; Xuebing Sun; Ye Liu; Fenglong Yu; Wenfeng Gong; Yong Liu; Beibei Jiang; Tristin Tang; Ricky Patel; Leonidas C Platanias; C David James; Roger Stupp; Rimas V Lukas; David C Binder; Derek A Wainwright
Journal:  Clin Cancer Res       Date:  2018-03-02       Impact factor: 12.531

6.  Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.

Authors:  María González-Tablas Pimenta; Álvaro Otero; Daniel Angel Arandia Guzman; Daniel Pascual-Argente; Laura Ruíz Martín; Pablo Sousa-Casasnovas; Andoni García-Martin; Juan Carlos Roa Montes de Oca; Javier Villaseñor-Ledezma; Luis Torres Carretero; Maria Almeida; Javie Ortiz; Adelaida Nieto; Alberto Orfao; María Dolores Tabernero
Journal:  Brain Pathol       Date:  2021-02-13       Impact factor: 6.508

7.  Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma.

Authors:  Lijie Zhai; April Bell; Erik Ladomersky; Kristen L Lauing; Lakshmi Bollu; Brenda Nguyen; Matthew Genet; Miri Kim; Peiwen Chen; Xinlei Mi; Jennifer D Wu; Matthew J Schipma; Brian Wray; John Griffiths; Richard D Unwin; Simon J Clark; Rajesh Acharya; Riyue Bao; Craig Horbinski; Rimas V Lukas; Gary E Schiltz; Derek A Wainwright
Journal:  Clin Cancer Res       Date:  2021-09-03       Impact factor: 12.531

Review 8.  Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms.

Authors:  Rong En Tay; Emma K Richardson; Han Chong Toh
Journal:  Cancer Gene Ther       Date:  2020-05-27       Impact factor: 5.987

9.  Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing.

Authors:  Matthias Jürgen Schmitt; Carlos Company; Yuliia Dramaretska; Iros Barozzi; Andreas Göhrig; Sonia Kertalli; Melanie Großmann; Heike Naumann; Maria Pilar Sanchez-Bailon; Danielle Hulsman; Rainer Glass; Massimo Squatrito; Michela Serresi; Gaetano Gargiulo
Journal:  Cancer Discov       Date:  2020-12-23       Impact factor: 39.397

10.  SETDB1 promotes glioblastoma growth via CSF-1-dependent macrophage recruitment by activating the AKT/mTOR signaling pathway.

Authors:  Shuai Han; Wei Zhen; Tongqi Guo; Jianjun Zou; Fuyong Li
Journal:  J Exp Clin Cancer Res       Date:  2020-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.